CASI Pharmaceuticals Report Positive Interim Phase 1 Data For BI-1206 In The Treatment Of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma In China [Yahoo! Finance]
CASI Pharmaceuticals, Inc. - Ordinary Shares (CASI)
Last casi pharmaceuticals, inc. - ordinary shares earnings: 11/12 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
casipharmaceuticals.com/investor-relations
Company Research
Source: Yahoo! Finance
development and commercialization of innovative therapeutic and pharmaceutical products, and BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announced preliminary encouraging efficacy data for BI-1206 in combination with rituximab in patients with relapsed/refractory (R/R) indolent Non-Hodgkin's Lymphoma (iNHL) in the ongoing development program in China BI-1206 is a first-in-class fully human monoclonal antibody (mAb) that targets Fc?RIIB. It is being evaluated in combination with rituximab in patients with R/R iNHL. The Phase 1 study is designed to assess the safety, tolerability, pharmacology, and clinical activity of BI-1206, administered though intravenous (IV) infusion. The Phase 1 dose-escalation study showed impressive signs of clinical efficacy, with 4 partial responses (PR) and 1 complete response (CR) out
Show less
Read more
Impact Snapshot
Event Time:
CASI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CASI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CASI alerts
High impacting CASI Pharmaceuticals, Inc. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
CASI
News
- Analysts Are Optimistic We'll See A Profit From CASI Pharmaceuticals, Inc. (NASDAQ:CASI) [Yahoo! Finance]Yahoo! Finance
- BioInvent International AB: Interim Report January-March 2024 [Yahoo! Finance]Yahoo! Finance
- CASI PHARMACEUTICALS REPORTS DEVELOPMENT RELATING TO ITS DISPUTES WITH JUVENTAS [Yahoo! Finance]Yahoo! Finance
- CASI PHARMACEUTICALS REPORTS DEVELOPMENT RELATING TO ITS DISPUTES WITH JUVENTASPR Newswire
- CASI Pharmaceuticals, Inc. (NASDAQ: CASI) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
CASI
Earnings
- 11/14/23 - Beat
CASI
Sec Filings
- 4/8/24 - Form 6-K
- 3/28/24 - Form 6-K
- 3/28/24 - Form 20-F
- CASI's page on the SEC website